A detailed history of Dimensional Fund Advisors LP transactions in Medicinova Inc stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 107,694 shares of MNOV stock, worth $150,771. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,694
Previous 152,530 29.39%
Holding current value
$150,771
Previous $228,000 31.58%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.28 - $1.65 $57,390 - $73,979
-44,836 Reduced 29.39%
107,694 $156,000
Q4 2023

Feb 07, 2024

SELL
$1.38 - $2.06 $7,468 - $11,148
-5,412 Reduced 3.43%
152,530 $228,000
Q3 2023

Nov 09, 2023

BUY
$2.01 - $2.6 $86,769 - $112,239
43,169 Added 37.61%
157,942 $330,000
Q2 2023

Aug 09, 2023

BUY
$2.09 - $2.43 $9,900 - $11,510
4,737 Added 4.3%
114,773 $263,000
Q1 2023

May 12, 2023

BUY
$1.95 - $2.54 $68,310 - $88,978
35,031 Added 46.7%
110,036 $237,000
Q4 2022

Feb 09, 2023

BUY
$1.97 - $2.66 $56,944 - $76,889
28,906 Added 62.7%
75,005 $153,000
Q3 2022

Nov 10, 2022

SELL
$2.1 - $2.6 $5,407 - $6,695
-2,575 Reduced 5.29%
46,099 $100,000
Q2 2022

Aug 12, 2022

SELL
$2.31 - $3.14 $4,389 - $5,966
-1,900 Reduced 3.76%
48,674 $123,000
Q1 2022

May 13, 2022

SELL
$2.19 - $2.81 $9,375 - $12,029
-4,281 Reduced 7.8%
50,574 $135,000
Q4 2021

Feb 09, 2022

BUY
$2.61 - $4.42 $843 - $1,427
323 Added 0.59%
54,855 $147,000
Q3 2021

Nov 12, 2021

BUY
$3.4 - $4.24 $105,610 - $131,702
31,062 Added 132.35%
54,532 $207,000
Q2 2021

Aug 12, 2021

SELL
$3.76 - $5.14 $14,265 - $19,501
-3,794 Reduced 13.92%
23,470 $100,000
Q1 2021

May 14, 2021

BUY
$4.81 - $8.74 $17,797 - $32,338
3,700 Added 15.7%
27,264 $138,000
Q4 2020

Feb 25, 2021

BUY
$5.03 - $6.31 $118,526 - $148,688
23,564 New
23,564 $124,000

Others Institutions Holding MNOV

About MEDICINOVA INC


  • Ticker MNOV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,046,200
  • Market Cap $68.7M
  • Description
  • MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...
More about MNOV
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.